(NASDAQ: ALVO) Alvotech's forecast annual revenue growth rate of 31.9% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.53%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.83%.
Alvotech's revenue in 2025 is $562,478,000.On average, 2 Wall Street analysts forecast ALVO's revenue for 2025 to be $206,523,012,848, with the lowest ALVO revenue forecast at $197,866,732,790, and the highest ALVO revenue forecast at $215,179,292,906. On average, 1 Wall Street analysts forecast ALVO's revenue for 2026 to be $300,813,522,049, with the lowest ALVO revenue forecast at $300,813,522,049, and the highest ALVO revenue forecast at $300,813,522,049.
In 2027, ALVO is forecast to generate $403,741,615,238 in revenue, with the lowest revenue forecast at $403,741,615,238 and the highest revenue forecast at $403,741,615,238.